Jason P. Schrum, Phd Email & Phone Number

Kirkland, Wa, Us

New York, New York, Us

- Lead matrixed cross-functional Translational Science Teams across early-stage (CAN-PhII) oncology antibody-drug conjugate (ADC) programs, including strategies to support clinical development, IND-readiness, resourcing, and regulatory filings (~2-4 IND submissions annually) - Represent Translational Sciences functions at Global Product and Development Teams and relevant program review and executive governance bodies

Thuwal, Makkah, Sa

Thuwal, Makkah, Sa

Biological and Environment Sciences and Engineering (US-based) - Designed and developed business plan, operating and funding model for the first private clinical genomics company in Saudi Arabia (https://www.noordx.sa/) - Successfully raised 2M SAR (500K USD) seed fund, facilitating Series A of c.20M SAR (5.3M USD) - Established 5 pre-launch partnerships (undisclosed) with top-tier genomics institutes and health techs in USA, France, and Australia; drafted, negotiated, executed contracts and term sheetsIndustry Collaborations, Innovation & Economic Development (Saudi-based) - Oversaw industry collaboration and partnership activity (~50+ industry companies) across 11 KAUST Engineering Research Centers; led a team of 3 PhD-level professionals and 11 industry liaisons - Managed the industry partner portfolio in key areas of focus across KSA (healthcare, materials chemistry, energy, water desalination); contributed to strategic life science roadmap Integrative Activities, Office of Competitive Research Funds (Saudi-based) - Developed bold, interdisciplinary research initiatives (~$10M) in multiple science and engineering domains; program yielded >50 faculty publications and additional patent applications pending (2016-2017) - Partnered with US National Academy of Sciences, Office of Naval Research – Global (ONR-G), Saudi Arabia General Investment Authority (SAGIA) - Comprehensive business process mapping analyses across 7 work streams, 46 FTEs, and successfully introduced new methods and workflows; introduced integrated research management platform (MIT COEUS)

New York, New York, Us

Office of BioTherapeutics R&D SVP and Pfizer Cambridge Site Head Executive Group - Managed translational research activities across 4 Research Units and 3 Partner Lines to support BioTx operating model (End-to-End Biologics) and progression of the portfolio across early development (LD/CAN - PoC PhIIb); therapeutics areas: Immunology & Inflammation; Rare Disease; Oncology; Neuroscience - Developed 23andMe 10K IBD and 5K Lupus patient communities; extended Research Accelerator to support patient-centric approach to Precision Medicine - Led the MIT Synthetic Biology Center alliance to support streamlined biologic production capabilities through the technology transfer of proprietary genomic excision and targeted gene integration technology - Explored new ventures with VC/PE firms to support spin-in of technologies to support or complement PFE clinical research, development, and precision medicine priorities - Managed the BioTherapeutics R&D Drug Discovery Meeting to provide project and partner line teams a review forum with scientific and clinical leaders from top academic and medical institutions

Cambridge, Massachusetts, Us

- Founded and recruited R&D team; initiated start-up research operations, regulatory filings, and CRO projects; scouted and co-designed incubator facility build-out - Led founding research team in preliminary pharmacology POC technology studies with discovery stage preclinical assets; created and developed an extensive database of over 200 potential preclinical pipeline candidates - Lead inventor on 23 issued and pending patents across a broad range of DNA and RNA technologies and therapeutic applications via coordinated R&D and business strategy - Managed seed financing and individual research project budgets

Cambridge, Ma, Us

Venture Capital and Private Equity FirmPerformed in-depth market, technology, and IP analyses to support the launch of life science NewCosCollaborated directly with Flagship Venture Partners and academic leads at Harvard, MIT, and MGH

Boston, Ma, Us

Developed a chemical method of synthetic DNA replication in a cell-like nanoparticleContributed to the development of the NSF Chemical Bonding Center Phase I

Boston, Ma, Us

Dissertation Advisor: Jack W. Szostak, 2009 Nobel Laureate in Medicine.Worked with Frederick W. Alt, Charles A. Janeway Professor of Pediatrics at Children's Hospital Boston

Advisor: Kathryn W. Tosney

Phd, Biological Chemistry And Molecular Pharmacology

Bs, Cellular And Molecular Biology With High Honors

Bm, Music History

Bma, Harpsichord Performance